Amyloid-Beta Immunotherapies for Alzheimer's Disease: Current Progress - PubMed
19 hours ago
- #amyloid-beta immunotherapy
- #Alzheimer's disease
- #clinical trials
- Amyloid-Beta (Aβ) accumulation is a key factor in Alzheimer's Disease (AD) pathophysiology and progression.
- Immunotherapies targeting Aβ have emerged as potential disease-modifying drugs, with both active (vaccines) and passive (monoclonal antibodies) approaches developed.
- Early Aβ vaccines and monoclonal antibodies faced safety issues like ARIA and variable efficacy, leading to discontinuations but guiding refinements in later generations.
- Recent approvals include Aduhelm® (Aducanumab), Leqembi® (Lecanemab), and Kisunla® (Donanemab), which reduce Aβ burden and slow cognitive decline, though benefits are modest.
- Challenges remain in patient selection, biomarker monitoring, ARIA risk reduction, long-term outcomes, and global accessibility, with uncertainty about meaningful long-term disease modification.